> R&D > Pipeline > AR153
pH-Dependent Antibody
• A novel strategy to enhance tumor specificity of ADCs
• Improved safety and Therapeutic Index (TI) through ADCs based on pH-dependent antibodies
• Change in affinity of pH-dependent anti-B7-H3 antibody depending on pH and structural analysis of B7-H3 binding region
• Tissue distribution studies confirming the superior tumor-selective penetration ability of pH-dependent antibody.
• Complete remission (CR) was observed in a mouse tumor model using a pH-responsive anti-B7-H3 ADC conjugated with the MMAE drug payload, with no safety-related issues reported.
